Compare Ishares Msci Spain ETF (EWP) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Spain ETF vs TG Therapeutics Inc — how do they compare? Ishares Msci Spain ETF trades at $57.87 (market cap $2.30B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 3.5× Ishares Msci Spain ETF's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Ishares Msci Spain ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Spain ETF for 41 Days and TG Therapeutics Inc for 16 Days on average.
| EWP | TGTX | |
|---|---|---|
Market Cap | $2.30B | $8.16B |
Volume | 845,747 | 1,735,121 |
Sector | Broad Market / Factor | Health |
52-Week High | $63.23 | $59.06 |
52-Week Low | $48.33 | $26.94 |
Typical Hold Time | 41 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWP, the iShares MSCI Spain ETF, trades at $57.90 with minimal daily movement (+0.14%). Technical indicators show a bearish trend with strong selling pressure across moving averages and oscillators. The ETF offers exposure to Spanish equities at a discounted valuation with a 2.7% yield, though concentrated in financials and utilities. Recent ECB rate hikes and energy price volatility create macroeconomic headwinds for European markets.
The outlook remains cautious given bearish technical signals and eurozone economic pressures. Attractive valuation and dividend yield provide support, but concentration risk and monetary policy tightening pose challenges. Further upside depends on Spanish economic resilience and stabilization of energy inflation.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ishares Msci Spain ETF
EWP is a country-specific ETF that tracks the performance of the Spanish equity market. It provides targeted access to large and mid-sized companies in Spain, with heavy weightings in financials and utilities like Banco Santander and Iberdrola.
Read more on EWP →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
